IκBα targeting promotes oxidative stress-dependent cell death

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Oxidative stress, driven by reactive oxygen species (ROS), is a key feature of many cancers.
• Increased mitochondrial respiration elevates ROS, influencing cell fate and cancer progression.
• Chemotherapy utilizes ROS generation as an anticancer mechanism.

Purpose of the Study:

• To investigate the role of NFKBIA and its encoded protein IκBα in cancer.
• To explore the correlation between IκBα, oxidative metabolism, and ROS production in lung cancer.
• To develop novel therapeutic strategies targeting IκBα for cancer treatment.

Main Methods:

• In silico analyses to identify NFKBIA amplification.
• RNA-silencing, xenotransplantation, Western blot, immunohistochemistry, and RT-qPCR to assess gene and protein expression.
• Immunoprecipitation and pull-down assays to evaluate protein-protein interactions.

Main Results:

• Identified NFKBIA amplification and an inverse correlation between IκBα, oxidative metabolism, and ROS in lung cancer.
• Demonstrated that IκBα-targeting compounds combined with cisplatin induce lethal levels of ROS (oxytosis).
• Characterized a unique cancer subtype defined by NFKBIA amplification and IκBα overexpression.

Conclusions:

• NFKBIA amplification and IκBα overexpression define a distinct cancer subtype with specific metabolic signatures.
• IκBα overexpression, via p65-NFKB regulation, promotes metabolic rewiring and alters cisplatin susceptibility.
• A novel approach to disrupt IκBα/p65 interaction restores apoptotic responses to cisplatin by deregulating mitochondria and increasing ROS.